# Day One Biopharmaceuticals, Inc. > Clarifo company profile — qualitative business description generated from > the company's filings. Financial statements, charts and ratios are > available on Clarifo (https://www.clarifo.com/fi/companies/Day One Biopharmaceuticals, Inc.). ## Overview Day One Biopharmaceuticals is a U.S.-based commercial-stage biopharmaceutical company focused on targeted therapies for childhood and adult cancers. Its current business centers on OJEMDA for relapsed or refractory pediatric low-grade glioma and on advancing a pipeline that includes DAY301 and other oncology programs through in-licensing, clinical development, and selective partnerships. ## Products & services • OJEMDA (tovorafenib) for relapsed/refractory pLGG • DAY301, a PTK7-targeting antibody-drug conjugate • VRK1 inhibitor program • Pimasertib development program • Out-licensing / commercialization partnerships outside the U.S. - **Commercial oncology product** (100%) — OJEMDA is the company’s approved product for relapsed or refractory pLGG in the U.S. - **Clinical-stage oncology pipeline** (0%) — Includes DAY301, the VRK1 inhibitor program, and other development assets. - **Out-licensing and collaboration revenue** (0%) — License and service revenue from partnering rights outside the U.S. and related R&D services. - OJEMDA (tovorafenib) for relapsed/refractory pediatric low-grade glioma - DAY301 PTK7-targeting antibody-drug conjugate in Phase 1a/b - VRK1 inhibitor program in preclinical/early development - Pimasertib program tracked as an R&D asset - Ex-U.S. commercialization of OJEMDA through Ipsen - Clinical development and manufacturing services for partnered programs ## Customers Day One sells primarily into a narrow specialist oncology channel in the United States, where pLGG is treated by a focused group of pediatric and neuro-oncology specialists. Its access and distribution model also depends on managed care, government payers, hospital systems, specialty distributors, and specialty pharmacies to secure coverage and patient access. Outside the U.S., the company relies on Ipsen to commercialize OJEMDA, so the end customer base is reached through a partner rather than Day One’s own sales force. - **U.S. specialist physicians** (primary) — Pediatric and neuro-oncology specialists prescribe OJEMDA for relapsed/refractory pLGG and drive adoption. - **Payers and access organizations** (primary) — Managed care, government payers, and hospital systems influence coverage, reimbursement, and patient access. - **Specialty distribution channel** (secondary) — Specialty pharmacies and distributors dispense OJEMDA and support the narrow rare-disease channel. - **International partner Ipsen** (secondary) — Ipsen commercializes OJEMDA outside the U.S. under the license agreement. - **Clinical trial investigators and sites** (secondary) — Investigators and trial sites enroll patients for DAY301 and other pipeline programs. - Pediatric and neuro-oncology specialists treating pLGG - Hospital systems and cancer centers that diagnose and treat rare tumors - Managed care and government payers that determine coverage and reimbursement - Specialty pharmacies and specialty distributors that handle dispensing - Ipsen as ex-U.S. commercialization partner for OJEMDA ## Geography Day One is headquartered in Brisbane, California and generates product revenue primarily in the United States from OJEMDA. Internationally, the company has licensed ex-U.S. commercialization rights for OJEMDA to Ipsen, which shifts non-U.S. market execution and some regulatory/commercial risk to a partner. Its pipeline also depends on global third-party manufacturers and collaborators, including MabCare in Shanghai, China. - Headquartered in Brisbane, California, United States - U.S. is the core commercial market for OJEMDA - Ex-U.S. OJEMDA commercialization is handled by Ipsen - MabCare in Shanghai, China is a key licensing counterparty - Third-party manufacturing and clinical operations are geographically distributed ## Strategy The company is transitioning from a development-focused biotech into a commercial oncology business built around OJEMDA while expanding its pipeline. Its strategy is to source differentiated assets through business development, move them through clinical development, and use partnerships where they improve speed or market reach. Day One also aims to keep a lean U.S. commercial footprint by focusing on a concentrated specialist channel and outsourcing ex-U.S. commercialization to Ipsen. - **Expand OJEMDA commercial adoption in the U.S.** (short-term) — The company’s near-term revenue base depends on penetration of the small specialist pLGG market and payer access. - **Advance DAY301 into clinical development** (medium-term) — Pipeline progression is needed to diversify the company beyond a single commercial asset. - **Source additional oncology assets through business development** (medium-term) — In-licensing can expand the pipeline faster than internal discovery alone. - **Use partnerships to maximize ex-U.S. value** (medium-term) — Partnering reduces the need to build international commercial infrastructure and can accelerate market entry. - Grow OJEMDA adoption in the U.S. rare-disease specialist channel - Use business development to add first- or best-in-class oncology assets - Advance DAY301 and other pipeline programs through clinical proof-of-concept - Partner outside the U.S. to extend reach without building a large global sales force - Rely on third parties for manufacturing and selected development services ## Risks Day One faces the typical risks of a commercial-stage biotech with a short operating history: dependence on a single approved product, uncertain clinical outcomes for pipeline assets, and heavy reliance on third parties for manufacturing and trial execution. Commercial success also depends on payer coverage, regulatory approvals, patent protection, and the company’s ability to scale operations without losing focus or talent. - **Dependence on OJEMDA as the only commercial product** [high] — A single-product revenue base makes the business sensitive to launch execution, payer access, and competitive or regulatory setbacks. - **Clinical development failure for DAY301 and other pipeline assets** [high] — The company’s growth strategy relies on successful trial results and regulatory approval for new programs. - **Third-party manufacturing and supply chain disruption** [high] — The company depends on external manufacturers for product and candidate supply, which can delay trials or commercial shipments. - **Reimbursement and pricing pressure** [medium] — Coverage restrictions, rebates, and government cost containment can reduce realized net revenue. - **Patent and exclusivity erosion** [high] — Loss of IP protection or exclusivity would weaken the company’s ability to defend OJEMDA and future products. - OJEMDA concentration risk: current revenue depends on one commercial product - Clinical failure risk: DAY301 and other programs may not show efficacy or safety - Manufacturing risk: third-party supply issues could disrupt trials or sales - Reimbursement risk: payer coverage and pricing pressure can limit uptake - IP risk: patent or exclusivity challenges could enable competition ## Accounting The most important accounting judgments are revenue recognition for OJEMDA product sales, the Ipsen license arrangement, and accruals for clinical trial costs. Because the company is still building its commercial base, estimates for discounts, rebates, chargebacks, returns, and specialty distribution fees can materially affect reported net revenue and quarter-to-quarter comparability. Clinical trial accruals are also judgment-heavy because management estimates work performed by CROs before invoices are received. - **Net product revenue deductions** — Can materially change reported revenue and gross-to-net trends - **License revenue from Ipsen** — Can create upfront revenue followed by deferred recognition over time - **Accrued research and development expense** — Affects R&D expense and liabilities when trial activity changes - **Commercial launch seasonality and comparability** — Makes period-to-period revenue and margin comparisons less stable - Net product revenue depends on estimates for rebates, chargebacks, and returns - Ipsen license revenue may be recognized upfront and over time depending on services - Clinical trial accruals rely on estimates of work completed by CROs - R&D expense timing can shift with enrollment and trial activity - Commercial launch phase can create quarter-to-quarter revenue volatility --- *Last updated: 2026-04-28T20:01:35.781862+00:00*